Special Issue "DNA Vaccines"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (15 May 2013)
Prof. Dr. Margaret A. Liu
1 ProTherImmune, 3656 Happy Valley Road Lafayette, CA 94549, USA 2 Karolinska Institute, Stockholm SE-17177, Sweden 3. Adjunct Professor, Department of Microbiology and Immunology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 USA
Website | E-Mail
Fax: +1 925 299 2959
Interests: vaccine technologies; DNA vaccines; cellular immune responses; HIV Vvccines; global health
During the last few years, there has been immense progress in the field of gene-based vaccines. This has been a result of new and better vectors, improved expression constructs, different types of delivery methods and devices, and it may be said, selection of optimal diseases/antigens and vaccinees. Several products have been licensed for veterinary applications, including infectious diseases and cancer. New human clinical trials have been initiated, and a number of phase 1-2 trials concluded. The present issue on “Research progress for gene-based vaccines” will bring together primary data and up-to-date summaries of break-throughs in using DNA plasmids for vaccines and immunotherapies. It will also show the possibilities of gene therapy, for which there is one licensed veterinary product and a different human one. To exemplify the progress, the situation for several severe infectious diseases and tumors will be depicted together with future views for further translation into the clinic.
It is 20 years since the first data on DNA vaccines were publicly presented at Cold Spring Harbor, 1992. Clinical trials of DNA vaccines are in progress for many diseases including HIV, HCV, malaria, influenza, tuberculosis and tumors (colo-rectal, prostate, melanoma). These include plasmid constructs used as a prime for boosting with other types of vaccines.
Prof. Dr. Margaret A. Liu
Prof. Dr. Britta Wahren
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- DNA vaccine
- RNA vaccine
- infectious diseases
- autoimmune diseases
- immune mechanisms
- T cells
- innate immunity
- delivery technology